Cord Blood Antibodies Following Bbibp-Corv (Sinopharm) Vaccination During Pregnancy Publisher Pubmed



Hantoushzadeh S¹ ; Eshraghi N¹ ; Younesi S² ; Salehi M³ ; Rezaei N⁴ ; Hasheminejad MM¹ ; Rashidian P¹ ; Shirdel S¹ ; Asadi F¹ ; Ghaemi M¹ Show Affiliations
Source: Immunity# Inflammation and Disease Published:2023

Abstract

Objective: This study aimed to evaluate the maternal and umbilical cord blood antibody levels, after COVID vaccination during pregnancy. Method: The women who received the COVID-19 vaccine (Sinopharm) during pregnancy were included. Maternal and cord blood samples were tested to detect the severe acute respiratory syndrome coronavirus 2 receptor binding domain (RBD) specific antibodies. In addition, obstetric information and side effects after vaccination were gathered. Result: A total of 23 women were included. Eleven pregnant women took two doses and 12 cases received a single dose of the vaccine. No IgM antibody was detected in any maternal blood or cord blood samples. The RBD-specific Immunoglobulin G (IgG) antibody was positive in mothers receiving 2 doses of the vaccine and their infants. But the antibody titers were under the positive cut-off threshold for the other 12 women who were vaccinated with a single dose. Women who received both doses of vaccine had significantly higher IgG levels than a single dose of Sinopharm (p =.025). The same result was demonstrated in infants born to these mothers (p =.019). Conclusion: There was a significant correlation between maternal and neonatal IgG concentrations. Although, receiving both doses of the BBIBP-CorV vaccine (not 1 dose) during pregnancy is highly beneficial for increasing humoral immunity for the mother and fetus. © 2023 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.